HIGHLIGHTS

3267  Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

3269  A PERFECT Biomarker-focused Study of Neoadjuvant IO for Esophagogastric Cancer
Daniel V.T. Catenacci
See related article, p. 3351

3272  Molecular Subtypes of Pancreatic Cancer: A Proteomics Approach
Ravi Thakur and Pankaj K. Singh
See related article, p. 3370

3275  Answers Are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer
Hope S. Rugo and Laura Huppert
See related article, p. 3404

3278  Can Biomarkers Guide Oncolytic Virus Immunotherapy?
Howard L. Kaufman
See related article, p. 3432

Reviews

3280  APOBEC and Cancer Virommunotherapy: Thinking the Unthinkable
Richard G. Vile, Alan Melcher, Hardev Pandha, Kevin J. Harrington, and Jose S. Pulido

3291  Therapeutic Manipulation of Tumor-associated Macrophages: Facts and Hopes from a Clinical and Translational Perspective
Paola Allavena, Clément Anfray, Aldo Ummarino, and Fernando Torres Andón

CLINICAL TRIALS: TARGETED THERAPY

3298  Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas

3307  Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
Erline K. Seymour, Husain Yar Khan, Yiwei Li, Mahmoud Chaker, Irfana Muqbil, Amro Aboukameel, Radhakrishanan Ramchandren, Christiane Houde, Golbon Sterbis, Jay Yang, Divaya Bhutani, Silvana Pregia, Kathy Reichel, Amy Huddleston, Colleen Neveux, Kelly Corona, Yosef Landesman, Jatin Shah, Michael Kaufman, Sharon Shacham, Ramzi M. Mohammad, Asfar S. Azmi, and Jeffrey A. Zonder

3317  Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma
3329 Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lorholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, and Jennifer R. Diamond

3339 Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

3351 Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

3360 Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

3370 A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry
Minsoo Son, Hongbeom Kim, Dohyun Han, Yoseop Kim, Iksoo Huh, Youngmin Han, Seung-Mo Hong, Woon Kwon, Haeryoung Kim, Jin-Young Jang, and Youngsoo Kim
See related commentary, p. 3272

3383 Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models
Gang Yang, Wenfeng Guan, Zhe Cao, Wenbo Guo, Guangbing Xiong, Fangyu Zhao, Mengyu Feng, Jiandong Qiu, Yueze Liu, Michael Q. Zhang, Lei You, Taiping Zhang, Yupei Zhao, and Jin Gu

3397 Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)
Wenxin Xu, Mâneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert G. Uzzo, Janice P. Dutcher, Robert S. DiPaola, Venkata Sabbisetti, and Rupal S. Bhatt

3404 Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer
Neelima Vidula, Andrzej Niemierko, Giuliana Malvarosa, Megan Yuen, Jochen Lennerz, A. John Iafrate, Seth A. Wander, Laura Spring, Dejan Juric, Steven Isakoff, Jerry Younger, Beverly Moy, Leif W. Ellisen, and Aditya Bardia
See related commentary, p. 3275

3414 Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary

3422 Artificial Intelligence-Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer
Christopher J.M. Williams, Jenny F. Seligmann, Faye Elliott, Michael Shires, Susan D. Richman, Sarah Brown, Liping Zhang, Shalini Singh, Judith Pugh, Xiao-Meng Xu, Andrea Muranyi, Christoph Guetter, Auranuch Larsaksuk, Uday Kurkure, Zuo Zhao, Jim Martin, Xingwei Wang, Kien Nguyen, Wen-Wei Liu, Dongyao Yan, Nicholas P. West, Jennifer H. Barrett, Michael Barnes, Isaac Bai, Matthew T. Seymour, Philip Quirke, and Kandavel Shanmugam

See related commentary, p. 3275
Mutations in the IFN-γ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment
Tan-Trieu Nguyen, LeeAnn Ramsay, Mozhdeh Ahanfesh-Adams, Mathieu Lajoie, Dirk Schadendorf, Tommy Alain, and Ian R. Watson
See related commentary, p. 3278

Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET)
Claudio Vernieri, Federico Nichetti, Luca Lalli, Luca Moscetti, Carlo Alberto Giorgi, Gaia Griguolo, Antonio Marra, Giovanni Randon, Carmen G. Rea, Francesca Ligorio, Simone Scagnoli, Claudia De Angelis, Chiara Molinelli, Agnese Fabbrì, Emanuela Ferraro, Dario Trapani, Andrea Milani, Elisa Agostinetto, Ottavia Bernocchi, Giovanna Catania, Amelia Vantaggiato, Michela Palleschi, Anna Moretti, Debora Basile, Marika Cinausero, Arta Ajazi, Lorenzo Castagnoli, Salvatore Lo Vullo, Lorenzo Gerratana, Fabio Puglisi, Nicolà La Verde, Grazia Argino, Andrea Rocca, Mariangela Ciccarese, Rebecca Pedersini, Alessandra Fabi, Daniele Generali, Agnese Losurdo, Filippo Montemurro, Giuseppe Curigliano, Lucia Del Mastro, Andrea Michelotti, Enrico Cortesi, Valentina Guarneri, Giancarlo Pruneri, Luigi Mariani, and Filippo de Braud

Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial
Carina Strell, Dick Folkvaljon, Erik Holmberg, Aglaia Schiza, Viktoria Thurfell, Per Karlsson, Jonas Bergh, Troy Longmire, Shira Esther Eisman, Keith Cordner, Justin T. Whitfield, Gary Vanasse, Zhu A. Cao, and Ross L. Levine
ABOUT THE COVER

The cover shows an image of a mpMRI-visible PCa tumor analyzed using AI-driven analysis. This tumor has glandular structures composed of malignant cells that represent stroma and compact tumor architecture. Macrophage infiltration is pronounced in the malignant zones, whereas T-cell infiltration primarily is observed in the nonmalignant compartment. For details, see the article by Pachynski and colleagues on page 3478 of this issue.